Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Mol Cancer Res. 2018 Jul 12;16(11):1737–1749. doi: 10.1158/1541-7786.MCR-18-0392

Figure 4: Selenbp1 functions as an anti-metastatic factor.

Figure 4:

a. Knockdown of Selenbp1 in an intravenously injected TnonMet cell line (394T4), results in significantly increased lung weight three weeks post-lnjection. Each dot represents a mouse, and the bar is the mean. *** P <0.001,****P <0.0001

b. Increased total tumor mass of a TnonMet, cell line (394T4), with Selenbp1 knockdown is shown by tdTomato fluorescent and H&E images. Fluorescent images, scale bar = 5 mm, H&E images, scale bar = 1mm.

c. Knockdown of Selenbp1 in a TnonMet cell line (394T4), intravenously injected, results in a slight but not significant increase in tumor number. Each dot represents a mouse, and the bar is the mean. NS = not significant.

d. Knockdown of Selenbp1 in a TnonMet cell line (394T4), intravenously injected, induces significantly larger tumors than control cells. Each dot represents a tumor, and the bar is the mean. *** P <0.0001

e. Tumor area is significantly higher after intravenous injection of a TnonMet cell line (394T4) compared to control cells. Each dot represents a mouse, and the bar is the mean. ** P <0.01